Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2024-05-07 AGM Information
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
AGM Information Classification · 1% confidence The document is a press release dated May 7, 2024, titled "Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A." and specifically discusses the formalities for making available and consulting preparatory documents for the meeting, including the agenda, draft resolutions (like dividend approval and director renewals), and voting conditions. This content directly relates to the materials provided to shareholders to inform their vote at the Annual General Meeting (AGM). While it mentions the publication of the notice of meeting, the core content is the information package for the upcoming AGM. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, or potentially Proxy Solicitation & Information Statement (PSI), but given the focus on the meeting itself and its preparatory documents, AGM-R is the most precise fit for the subject matter.
2024-05-07 English
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of April 30, 2024. This content directly relates to changes in the capital structure, specifically the total number of shares and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing report (DIRS).
2024-05-06 French
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information relative to the total number of voting rights and shares composing the share capital' and explicitly references compliance with French Commercial Code and AMF regulations. It provides a table detailing the total number of shares and voting rights as of a specific date (30 April 2024). This type of regular, mandatory disclosure regarding the composition of share capital and voting rights is a specific regulatory filing, often related to ownership changes or capital structure updates, but it does not fit perfectly into the defined categories like DIRS (Director's Dealing) or MRQ (Major Shareholding Notification), which focus on specific ownership changes or insider trades. Since it is a mandatory, periodic regulatory disclosure that doesn't fit the other specific codes (like 10-K, ER, DIV, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document is a report itself, not an announcement of a report, and its content is highly specific regulatory data.
2024-05-06 English
Ipsen appoints Keira Driansky as EVP, President of North America
Board/Management Information Classification · 1% confidence The document is a press release announcing a significant change in senior management: the appointment of Keira Driansky as EVP, President of North America. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The content focuses entirely on the executive appointment, background, and departure of the predecessor, with no financial statements or regulatory filing headers present.
2024-05-02 English
Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord
Board/Management Information Classification · 1% confidence The document is a press release announcing a significant change in senior management: the appointment of Keira Driansky as Executive Vice-President and President of North America, effective May 13, 2024. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a financial report (10-K, IR, ER), a proxy statement (DEF 14A), or a general regulatory filing (RNS), but a specific personnel announcement.
2024-05-02 French
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024
Earnings Release Classification · 1% confidence The document is titled "Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024" (Ipsen records solid first-quarter sales growth and confirms its financial targets for fiscal year 2024). It contains detailed financial tables showing revenue figures for Q1 2024 compared to Q1 2023, highlights of performance, confirmation of annual financial objectives, and a section on R&D pipeline updates. This structure—reporting on a specific, shorter fiscal period (Q1) with key financial metrics and management commentary—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it provides the initial announcement of the period's financial results (sales figures, highlights, and outlook confirmation) rather than a comprehensive, audited report, it aligns best with the Earnings Release (ER) definition. It is not a full Annual Report (10-K) or a standalone Audit Report (AR). It is also not merely an announcement of a report (RPA), as it contains the core results directly. Q1 2024
2024-04-24 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.